The EC domains of human fibrinogen420 contain calcium binding sites but lack polymerization pockets.

The extended (E) isoform unique to Fibrinogen420 (Fib420) is distinguished from the conventional chain of Fibrinogen340 by the presence of an additional 236-residue carboxyl terminus globular domain (EC). A recombinant form of EC (rEC), having a predicted mass of 27,653 Daltons, was expressed in yeast (Pichia pastoris) and purified by anion exchange column chromatography. Purified rEC appears to be predominantly intact, as judged by N-terminal sequence analysis, mass spectral analysis of the C-terminal cyanogen bromide (CNBr) fragment, and comparison of recognition by epitope-specific monoclonal antibodies. Carbohydrate determination, coupled with analysis of CNBr digestion fragments, confirms N-linked glycosylation at Asn667, the site at which sugar is attached in E. Analysis of CNBr digestion fragments confirms that two disulfide bridges exist at cysteine pairs E613/644 and E780/793. In the presence of 5 mmol/L EDTA, rEC is highly susceptible to plasmic degradation, but Ca2+ (5 mmol/L) renders rEC resistant. No protective effect from plasmic degradation was conferred to rEC by the peptides GPRPamide or GHRP, nor did rEC bind to a GPR peptide column. These results suggest that the EC domain contains a calcium-binding site, but lacks a polymerization pocket. By analogy with the site elucidated in the gammaC domain, we predict that the EC calcium binding site involves residues E772-778: DADQWEE.

Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2.

Anti-idiotype monoclonal antibodies (Mabs) to mLL2, an anti-B-cell lymphoma and CD22-specific murine IgG2a-kappa Mab, were generated by hybridoma technology from splenocytes of Copenhagen rats immunized with mLL2 F(ab')2. Mab WN, an IgG2a-kappa, was selected based on its specific binding to mLL2 and not other IgG isotypes or anti-B-cell Mabs. In a radioimmunoassay, WN was found to inhibit the binding of 125I-labeled mLL2 to Raji cells and to have no effect on the binding of other B-cell-reactive antibodies. Using high performance liquid chromatography analysis, WN was shown to complex specifically with both mLL2 and mLL2 Fab'. Meanwhile, we have constructed chimeric (cLL2) and humanized (hLL2) versions of LL2. Both cLL2 and hLL2 were demonstrated to retain the original antigen specificity and affinity of mLL2 [S.O. Leung et al., Proc. Am. Assoc. Cancer Res., 2872 (abstract), 34: 481, 1993]. The specific binding of WN to either radioiodinated or peroxidase-conjugated mLL2 was inhibited in a dose-response manner, and to a similar extent by mLL2, cLL2, and hLL2. Since the mLL2 complementarity-determining regions are the only sequences common to mLL2, cLL2, and hLL2, the result confirms that WN is specific to the antigen-binding complementarity-determining regions. A WN binding assay is currently being evaluated as a substitute for the tedious, and sometimes inconsistent, Raji cell-binding assay for the determination of LL2 immunoreactivity. In conclusion, we have developed an anti-idiotype Mab, WN, to mLL2. Its potential use as a surrogate antigen for B-cell lymphoma is under investigation.

The role of tumor angiogenesis factor (TAF) in the tumor growth. Pathological aspects.

This work was carried out on control and immunosuppressed A2G mice inoculated with murine tumour cells (Ehrlich ascites) and human ones (KB cell line). The growth of the tumours was conditioned by the growth of the fibrovascular stromas as a response of the host organism to the TAF secretion. This process is a nonimmunological response, the differences between control and immunosuppressed mice being of no statistical significance.

An experimental model comparing the antineoplastic and the immunosuppressive effects of some cytostatics.

An experimental model evaluating comparatively the antineoplastic and the immunosuppressive effects of some cytostatics (cyclophosphamide and vinblastine) is described in the present paper. Different cytostatic doses were intraperitoneally administered in mice which were 24 hours later grafted with a suspension of human tumoral KB cells. The xenograft acceptance was macroscopically and microscopically recorded 21 days later. By the Reed and Muench method and also by graphical extrapolation the LD50 (lethal dose for 50% animals) and the TD50 (the immunosuppressive dose enabling 50% animals to accept the xenografts) could thus be determined for both cyclophosphamide and vinblastine. The number (percent) of the tumour bearing animals three weeks after grafting was considered as an indicator of the cytostatic dose at which the immunosuppressive effect exceeded the antineoplastic effect. The in vitro effect of the same drugs on the KB cells was tested by inoculating different cytostatic doses in the cell cultures and counting at different time intervals the adherent as well as the nonadherent cells. The in vitro drug toxicity on the KB cell cultures was also determined by the trypan blue exclusion test. Both cyclophosphamide and vinblastine proved to be in vitro highly potent cytostatics i.e. when directly acting on the KB cells. This effect was dose correlated for both the considered drugs. However our in vivo experiments have shown that none of the observed effects when considering the direct action of the cytostatic on the cultured cells could not safely be extrapolated in vivo. Our results have an obvious practical importance when considering the therapeutical approaches in the neoplastic diseases. They demonstrate that the increase in cytostatic dose is not directly correlated to the antineoplastic effect since it reaches a limit at which the immunosuppressive effect highly exceed the tumour growth inhibition effect. The described experimental model could also be used in comparative estimations of the biological effects of different cytostatic drugs possibly referred to a standard immunosuppressive reagent as an antilymphocyte antiserum.